I thought this was interesting. If at first you don’t succeed, try, try again.
Risks to this story include the already mentioned FDA downthumb, resulting in the company needing to run additional studies and burn through more cash. Also, investors should be keeping a close eye on how enrollment for the other phase three programs is going. Primary completion is in October, representing another material catalyst.
I think they need to try different doses for the trials, for some drugs you need very specific doses to get the proper effect. Not just 60, 80, 120. Maybe at like 123.579 you will get the desired effect.
This medicine has/had the potential to revolutionize treatment for our disorders. I certainly hope it works if it does get approved. There have been some meds that were approved that simply do not work either. Geodon is one of those in my opinion.